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Abstract
Background: Over 15 inherited diseases are caused by expansion of triplet-repeats. Friedreich ataxia (FRDA) patients are
homozygous for an expanded GAA triplet-repeat sequence in intron 1 of the FXN gene. The expanded GAA triplet-repeat
results in deficiency of FXN gene transcription, which is reversed via administration of histone deacetylase inhibitors
indicating that transcriptional silencing is at least partially due to an epigenetic abnormality.
Methodology/Principal Findings: We found a severe depletion of the chromatin insulator protein CTCF (CCCTC-binding
factor) in the 59UTR of the FXN gene in FRDA, and coincident heterochromatin formation involving the +1 nucleosome via
enrichment of H3K9me3 and recruitment of heterochromatin protein 1. We identified FAST-1 (FXN Antisense Transcript – 1),
a novel antisense transcript that overlaps the CTCF binding site in the 59UTR, which was expressed at higher levels in FRDA.
The reciprocal relationship of deficient FXN transcript and higher levels of FAST-1 seen in FRDA was reproduced in normal
cells via knockdown of CTCF.
Conclusions/Significance: CTCF depletion constitutes an epigenetic switch that results in increased antisense transcription,
heterochromatin formation and transcriptional deficiency in FRDA. These findings provide a mechanistic basis for the
transcriptional silencing of the FXN gene in FRDA, and broaden our understanding of disease pathogenesis in triplet-repeat
diseases.
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Introduction
Friedreich ataxia (FRDA), the most common inherited ataxia, is
an autosomal recessive disease characterized by progressive
sensory ataxia, cardiomyopathy, diabetes, and premature death
[1]. FRDA is most commonly caused by inheriting an expanded
GAA triplet-repeat sequence in intron 1 of both copies of the FXN
gene [2]. The size of the expanded repeat tract can range from
66–1700 triplets, which results in a deficiency of FXN gene
transcription [3,4]. This in turn causes a deficiency of the
mitochondrial protein frataxin, which is essential for iron-sulfur
cluster biogenesis, and thereby results in mitochondrial dysfunc-
tion [1].
Exactly how FXN transcriptional silencing is achieved in FRDA
is not well understood, however recent evidence indicates that an
epigenetic abnormality is an important underlying mechanism. In
unrelated transgenic mouse experiments, the expanded GAA
triplet-repeat sequence was found to be a source of position effect
variegation (PEV) i.e., a source of heterochromatin spreading into
adjacent euchromatin [5]. Consistent with this observation,
evidence of heterochromatin formation was found in the
immediate vicinity of the expanded GAA triplet-repeat in cells
from FRDA patients [6–8]. More importantly, histone deacetylase
(HDAC) inhibitors resulted in partial reversal of the gene silencing
in patient-derived cells [6], indicating that heterochromatin
formation is an important underlying mechanism for the
transcriptional deficiency in FRDA. However, heterochromatin
formation has not been convincingly demonstrated in any region
other than intron 1 of the FXN gene in cells of FRDA patients, and
exactly how transcriptional silencing occurs is not fully understood.
Here, we report that FRDA patients have a severe depletion of
the chromatin insulator protein CTCF (CCCTC-binding factor)
in the 59 untranslated sequence (59UTR) of the FXN gene. We also
found that CTCF depletion was associated with higher levels of an
antisense transcript, and heterochromatin formation involving the
critical +1 nucleosome in the vicinity of the transcription start site
(TSS) of the FXN gene. Knockdown of CTCF reproduced the
deficiency of FXN gene transcription, and higher levels of antisense
transcription. Our data support the hypothesis that CTCF
depletion in FRDA constitutes an epigenetic switch that results
PLoS ONE | www.plosone.org 1 November 2009 | Volume 4 | Issue 11 | e7914in heterochromatin formation and deficiency of FXN gene
transcription.
Results
CTCF Is Depleted in the 59UTR of the FXN Gene in FRDA
Publicly available ChIP-on-CHIP data [9] revealed a single
CTCF binding site in the FXN gene that maps in the 59UTR
(+154 to +173, relative to the most proximal TSS [TSS1])
(Fig. 1A). Electrophoretic mobility shift assay (EMSA) using the
59UTR as a probe and HeLa nuclear extract showed a single
shifted complex (Fig. 1B). This complex was competed away with
an oligonucleotide probe containing the consensus CTCF-binding
site, but not with a control probe containing a mutant CTCF-
binding sequence (Fig. 1B), indicating that the shift was due to
CTCF binding in the 59UTR. Chromatin immunoprecipitation
(ChIP) with anti-CTCF using fibroblast cell lines from two normal
individuals showed considerable enrichment of CTCF in the
59UTR of the FXN gene in vivo, which was comparable to that seen
at the MYC locus, used as a positive control (Fig. 1C). Strikingly,
the same ChIP assay performed with fibroblast cell lines from two
FRDA patients, who were homozygous for expanded GAA triplet-
repeat sequences in intron 1 of the FXN gene, showed four-fold
reduced occupancy of CTCF in the 59UTR (Fig. 1D). These data
indicate that CTCF is depleted from the 59UTR of the FXN gene
in FRDA patients. Comparison of CTCF occupancy at the MYC
locus, and at another CTCF binding site at the APBA1 (Amyloid
beta A4 precursor protein-binding family A member 1) locus on
chromosome 9q, in FRDA versus normal cell lines did not show a
similar reduction, indicating that FRDA cells do not have a
generalized defect of CTCF binding (Fig. S1). DNA methylation is
known to interfere with CTCF binding [10], and there are two
CpG dinucleotides associated with the CTCF binding site in the
FXN 59UTR. Given that FRDA patients have increased CpG
methylation in intron 1 of the FXN gene [7,8], we investigated if
altered methylation in the 59UTR was a possible mechanism for
the depletion of CTCF. Bisulfite treatment, followed by sequenc-
ing of twelve individual clones from each of two FRDA and two
control fibroblasts, did not show any alteration in methylation
status at any of the nine CpG dinucleotides spanning the 59UTR
(including the two that overlap with the CTCF binding site), or in
the first six CpG sites of exon 1. Furthermore, EMSA performed
with HeLa nuclear extract and an in vitro methylated 59UTR
probe (methylation status of which was confirmed by bisulfite
sequencing) showed the same major complex obtained with the
unmethylated probe, which was competed away by excess cold
unmethylated probe (Fig. S2), indicating that altered DNA
methylation is unlikely to be the reason for CTCF depletion in
the FXN 59UTR in FRDA.
Heterochromatin Formation Involving the +1
Nucleosome of the FXN Gene in FRDA
We hypothesized that in FRDA patients depletion of CTCF, a
known chromatin insulator protein [10], would be associated with
heterochromatin formation in the 59UTR. Publicly available,
genome-wide, nucleosome occupancy data (nucleosome occupan-
Figure 1. Depletion of CTCF in the FXN 59UTR in FRDA. (A) Schematic representation of the relevant portion of the FXN gene showing the
CTCF binding site in the 59UTR, and the regions analyzed by EMSA and ChIP. All numbers are relative to TSS1. The region denoted as ‘‘Pro’’ is the
portion of the promoter/59UTR previously analyzed by other groups and shown not to have heterochromatin formation in FRDA [6,8]. (B) EMSA with
HeLa nuclear extract showing a single complex (arrow) that was competed with excess cold probe, CTCF binding oligonucleotide, but not with a
mutant CTCF oligonucleotide, indicating that CTCF binds in the FXN 59UTR. (C) ChIP with anti-CTCF in fibroblasts from non-FRDA controls showing
enrichment of CTCF in the FXN 59UTR in vivo. The CTCF insulator (MYC-N) and a non-binding site (MYC-G) in the MYC gene were used as positive and
negative controls for CTCF enrichment in vivo. The enrichment at the FXN 59UTR is comparable to the MYC locus. The GAPDH fragment used to
normalize the ChIP data did not show CTCF enrichment. (D) ChIP with anti-CTCF in fibroblasts from two non-FRDA control fibroblasts (CNTR) and two
FRDA patients showed significantly less occupancy of CTCF in FRDA. The data are from two independent chromatin preparations, with each
experiment done in triplicate. Error bars=s.e.m.; ‘‘*’’=P,0.05; ‘‘***’’=P,0.001.
doi:10.1371/journal.pone.0007914.g001
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+1 nucleosome of the FXN gene encompassed the CTCF binding
site in the 59UTR, which was preceded by a long nucleosome free
region containing the three reported TSS’s of the FXN gene
(denoted as TSS1-3 in Fig. 1A). ChIP followed by quantitative
PCR of the region spanning the +1 nucleosome showed significant
enrichment of histone modifications characteristic of heterochro-
matin formation specifically in FRDA cell lines. We detected
significant enrichment of H3K9me3 and H3K27me3 (Fig. 2A,B).
H3K9me3 is known to recruit heterochromatin protein 1 (HP1)
via interaction with the latter’s chromodomain. Indeed, we also
detected significant enrichment of HP1 (both a and c subunits
were tested and found to be enriched) in FRDA compared with
normal fibroblasts (Fig. 2C,D). These data indicate that CTCF
depletion in FRDA patients is associated with heterochromatin
formation involving the +1 nucleosome of the FXN gene.
FRDA Patients Have Higher Levels of FAST-1
As a potential mediator of heterochromatin formation, we
searched for an antisense transcript overlapping with the 59UTR
of the FXN gene. Strand-specific RT-PCR was carried out with a
primer located upstream of FXN TSS3 (Fig. 3A) and RNA from
normal fibroblasts, which revealed an antisense transcript that
overlapped with the CTCF binding site (Fig. 3A,B). We have
named this novel transcript FAST-1 (FXN Antisense Transcript –
1). No such product was detected in a ‘‘no-RT’’ reaction or in a
‘‘RT’’ reaction without exogenous primers (Fig. 3B), indicating
that this product was not amplified from contaminating DNA or
via spurious endogenous priming. Sequencing of the isolated
transcript showed that it was a perfect match to the antisense
strand of FXN, and BLAST analysis of this sequence showed only
a single hit (to the FXN locus), indicating that FAST-1 originates
from the FXN locus. RT-PCR experiments indicated that FAST-1
overlaps with the FXN gene, including at least portions of intron 1,
exon 1, the 59UTR, and extends further upstream into the
nucleosome free region and upstream of FXN TSS3 (until -343;
Fig. 3A). It is presently unclear if the putative polyadenylation
sequence located upstream of FXN TSS3 (2340; Fig. 3A) is
utilized by FAST-1. A tag corresponding to FAST-1 was identified
in a recent study of the human antisense transcriptome (position
70840691 on the ‘‘-’’ strand of chromosome 9 in the HCT116 cell
line) [14] (Papadopoulos, personal communication), which maps close
to the start of intron 1 of the FXN gene (Fig. 3A), and further
substantiates the existence of FAST-1. FAST-1 contains an open
reading frame which encodes a putative peptide of 154 amino
acids (70840410 to 70840874 on the ‘‘-’’ strand of chromosome 9,
which spans the antisense sequence tag isolated in [14]), with
homology to two uncharacterized open reading frames in rice.
The open reading frame extends from FXN intron 1, through exon
1, and ends in the 59UTR, and includes the CTCF binding site
(Fig. 3A). However, the importance of this open reading frame is
unclear since it is intact in human and chimpanzee, but contains
premature stop codons in orangutan, rhesus, and marmoset, and
the translational initiation site does not show a Kozak consensus
sequence.
We hypothesized that FRDA patients would have higher levels
of FAST-1, corresponding to the depletion of CTCF and
heterochromatin formation in the FXN 59UTR. Indeed, real-time
RT-PCR to measure FAST-1 levels in FRDA versus normal
fibroblasts revealed that patients had twice as much of this
antisense transcript (Fig. 3C). It should be noted that our data are
consistent with either actual overexpression of FAST-1, increased
spreading of FAST-1 upstream beyond the CTCF binding site, or
both.
CTCF Knockdown Reproduces the Deficiency of FXN
Transcript and Higher Levels of FAST-1 Seen in FRDA
Cells
In order to test if CTCF depletion is responsible for the
deficiency of FXN transcript and higher levels of FAST-1, as is
seen in FRDA patients, siRNA-mediated knockdown of CTCF
was performed in fibroblasts. Western blot analysis and quanti-
tative RT-PCR confirmed the global knockdown of CTCF (Fig.
S3, S4), and a micro-ChIP assay [15] was used to confirm
depletion of CTCF specifically in the 59UTR of the FXN gene (Fig.
S5). Real-time RT-PCR showed a significant reduction in the
levels of FXN transcript in siRNA treated fibroblasts from normal
individuals, but no further reduction was seen in FRDA cells
(Fig. 4A). This effect was unrelated to the transfection protocol per
se, since no such effect was seen with a scrambled sequence control
siRNA (Fig. S3, S4, S5, S6). Furthermore, real-time RT-PCR
showed a corresponding doubling of the levels of FAST-1 upon
siRNA knockdown in normal fibroblasts (Fig. 4B). Indeed, FAST-
1 levels in normal fibroblasts were equalized to the level seen in
FRDA cells via knockdown of CTCF. CTCF knockdown in
FRDA cells did not result in further increase in FAST-1 levels.
These data indicate that depletion of CTCF in normal cells is
capable of reproducing the reciprocal deficiency of FXN transcript
Figure 2. Heterochromatin formation in the FXN 59UTR in FRDA
patients. ChIP assays showing enrichment of (A) H3K9me3, (B)
H3K27me3, and (C,D) heterochromatin protein 1 subunits HP-1a and
HP-1c, specifically in FRDA fibroblast cell lines versus non-FRDA controls
(CNTR). All bars represent cumulative data from two fibroblast cell lines
(FRDA or non-FRDA control), ChIP performed in triplicate, on two
independent chromatin preparations. Error bars=s.e.m.; ‘‘*’’=P,0.05;
‘‘**’’=P,0.01.
doi:10.1371/journal.pone.0007914.g002
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seen naturally in FRDA cells.
Discussion
The expanded GAA triplet-repeat sequence results in deficiency
of FXN transcript via at least two mechanisms: deficient
transcriptional elongation through the expanded repeat tract
[3,16,17] and epigenetic silencing [6–8]. Previous studies detected
evidence of heterochromatin formation in the immediate vicinity
of the expanded GAA triplet-repeat in intron 1 in FRDA [6–8],
however, it has remained unclear how this results in transcrip-
tional silencing of the FXN gene. Our data are consistent with the
model that CTCF depletion in the 59UTR of the FXN gene in
FRDA patients results in reduced FXN transcription via
heterochromatin formation involving the critical +1 nucleosome,
which offers a plausible mechanism for transcriptional silencing of
the FXN gene, and is consistent with the observed transcriptional
reactivation via administration of HDAC inhibitors [6]. It is
interesting to note that previous unsuccessful attempts to detect
heterochromatin formation in the upstream regions of the FXN
gene in FRDA were directed to the nucleosome free region
immediately upstream of TSS1 [6,8]; the sequence we have
analyzed here is ,100 nucleotides downstream of this sequence,
and represents the +1 nucleosome (Fig. 1A). The +1 nucleosome is
an important regulator of transcription [18] and alteration of its
chromatin organization in FRDA has the possibility of influencing
FXN transcriptional initiation and/or elongation. It is also
interesting to note that heterochromatin formation in the vicinity
of the expanded GAA triplet-repeat in intron 1 of FRDA patients
is different from what we have observed in the 59UTR. The
former is associated with increased CpG methylation at specific
sites in intron 1, whereas we did not detect any alterations in DNA
methylation in the 59UTR. Instead, heterochromatin formation in
the 59UTR seems to be based on H3K9me3-mediated recruitment
of HP1.
Antisense transcripts have been implicated in heterochromatin
formation via H3K9me3 and subsequent recruitment of HP1
[19–21]. Most human genes are known to have transcripts that
emanate from, and head upstream of, their transcription start sites
[22–24]. However, these are technically not ‘‘antisense’’ tran-
scripts since they do not overlap with sense transcripts.
Nevertheless, ,15% of genes are known to have bona fide antisense
transcripts [14,25] that may serve to regulate the expression of
their corresponding sense transcripts. The discovery of FAST-1 is
therefore not surprising in itself, however, the detection of higher
levels of FAST-1 in the region showing heterochromatin formation
in FRDA patients offers a plausible mechanistic basis for the
epigenetic abnormality involving the +1 nucleosome [19–21].
Moreover, since knockdown of CTCF in normal fibroblasts
reproduced the increase in levels of FAST-1 seen in FRDA
fibroblasts, it suggests that CTCF depletion is required for
increased FAST-1 levels or spreading. Indeed, increased spread-
ing, or level of expression, of antisense transcripts has been shown
to induce epigenetic silencing of the corresponding ‘‘sense’’ gene.
A genomic deletion involving an intervening transcriptional
termination signal resulted in abnormal spreading of an antisense
transcript into the human a-globin gene and resulted in
Figure 3. FAST-1, an antisense transcript overlapping with the CTCF binding site, is present at higher levels in FRDA patients. (A, B)
Strand-specific RT-PCR showed the presence of an antisense transcript that overlaps with the FXN gene. The transcript extends at least from FXN
intron 1 to upstream of the FXN TSS. The solid line represents the part of the transcript (207-bp product in B) that we could amplify using one round
of PCR (with FAST-F1 and FAST-R1; see Methods), and the dotted line denotes the extended transcript that we detected via nested PCR. The FAST-1
product was not detected in a no-RT control (RT-), or when the RT reaction was performed without any exogenous primers (RTp-). The diamond
symbol represents a sequence tag corresponding to FAST-1, identified in the antisense transcriptome [11]. The gray bar represents the extent of an
open reading frame, and ‘‘pA’’ denotes a putative polyadenylation (pA) signal for FAST-1. All numbers are relative to TSS1. (C) Real-time RT-PCR (with
FAST-F1 and FAST-R1) showed twice as much FAST-1 levels in FRDA cell lines versus non-FRDA controls (CNTR). The bars represent cumulative data
from two fibroblast cell lines (FRDA or CNTR), RT-PCR in triplicate, from two independent experiments. Error bars=s.e.m.; ‘‘***’’=P,0.001.
doi:10.1371/journal.pone.0007914.g003
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[26]. Furthermore, the microRNA-mediated transcriptional si-
lencing via heterochromatin formation, which is well characterized
in S. pombe, is also conserved in mammalian cells [27], and most
likely results from targeting of the sense transcript, rather than the
genomic DNA itself [28]. Indeed, Yu et al. [29] directly
demonstrated that mammalian cells are capable of establishing
heterochromatin formation via overexpression of an antisense
transcript. Therefore, taken together, our data support the model
that CTCF depletion constitutes an epigenetic switch in FRDA
that allows increased expression or spreading of FAST-1,
heterochromatin formation involving the +1 nucleosome, and
transcriptional silencing of the FXN gene (Fig. 5).
CTCF, a multi zinc-finger protein, binds ,15,000 sites in the
h u m a ng e n o m e[ 9 ] .I n d e e d ,t h es i t ew ei d e n t i f i e di nt h eFXN 59UTR
is one of ,6,000 sites that are located in the vicinity of transcription
start sites of human genes. CTCF is a chromatin insulator that acts by
establishment of chromatin topological domains via CTCF-CTCF
interactions, and tethering to the nucleolar surface via CTCF-
nucleophosmin interactions. This higher-order chromatin organiza-
tion is known to regulate gene expression via creation of boundaries
in chromatin [30–32] such that they prevent (or facilitate) interactions
between enhancers and promoter sequences (enhancer-blocking
insulators), or by preventing the spread of heterochromatin (e.g. via
PEV) by creating a barrier between active and silenced chromatin
(barrier insulators). This higher-order organization afforded by
chromatin insulators is an important regulator of normal gene
expression [30–32]. Our data suggest various potential (non
mutually-exclusive) ways by which CTCF depletion could result in
heterochromatin formation and deficiency of FXN transcript. It is
possible that a CTCF-mediated, enhancer-blocking insulator nor-
mally keeps FAST-1 expression low. Local depletion of CTCF in
FRDA could disrupt this enhancer-blocking activity, allowing FAST-
1 overexpression (as occurs in the paternal IGF2 allele at the
imprinted H19-IGF2 locus). Another possibility is that CTCF
depletion in the FXN 59UTR could allow increased spreading of
FAST-1 to upstream sequences. FAST-1 overexpression or increased
spreading could result in heterochromatin formation and FXN gene
silencing via H3K9me3 and recruitment of HP-1 [19–21]. Indeed,
CTCF is known to limit the spread of an antisense transcript at the
human DMPK locus [33]. CTCF is displaced in the presence of very
large expansions of a nearby CTG triplet-repeat sequence, resulting
in spreading of antisense transcription and heterochromatin
formation beyond their limited confines, leading to congenital
myotonic dystrophy [33]. Another possibility is that the depletion
of CTCF in the 59UTR could disrupt a CTCF-mediated topological
segregation of the expanded GAA triplet-repeat, a known source of
PEV [5], from the 59UTR and TSS of the FXN gene. This would
allow the upstream spreading of heterochromatin from the expanded
GAA triplet-repeat in FRDA patients, thus resulting in FXN
transcriptional deficiency.
It remains unclear as to how the expanded GAA triplet-repeat,
the cause of FRDA [2], results in displacement of CTCF. Cohesin,
which is essential for sister chromatid cohesion [34], often
colocalizes with CTCF [35–37]. Cohesin also cooperates with
CTCF in regulating gene expression [38], and is required for
CTCF binding at some sites [35,36]. An intriguing possibility is
that the expanded GAA triplet-repeat sequence, possibly via
formation of a non-B DNA structure [3,16,39], may compromise
the loading, binding, or stability of cohesin and thereby promote
Figure 4. siRNA knockdown of CTCF in normal cells reproduces
the deficiency of FXN transcript and higher levels of FAST-1
seen in FRDA cells. All bars represent cumulative data from two
fibroblast cell lines (FRDA or CNTR), RT-PCR done in triplicate, from two
independent experiments. Error bars=s.e.m.; ‘‘**’’=P,0.01;
‘‘***’’=P,0.001. (A) Real-time RT-PCR showed that knockdown of
CTCF in normal fibroblasts (CNTR) resulted in significant reduction in
levels of FXN transcript, which was similar to that seen in FRDA
fibroblasts (the levels of FXN transcript in FRDA cells is similar to those
reported previously [6,17]). Knockdown of CTCF in FRDA cell lines
seemed to further reduce FXN transcript levels but this was not
statistically significant. (B) Real-time RT-PCR showed that knockdown of
CTCF in normal fibroblasts (CNTR) resulted in significant increase in
levels of FAST-1, which was similar to that seen in FRDA fibroblasts.
Knockdown of CTCF in FRDA cells did not further increase FAST-1 levels,
which remained around twice as high as in normal cells.
doi:10.1371/journal.pone.0007914.g004
Figure 5. CTCF depletion, increased FAST-1 level, and hetero-
chromatin formation in FRDA. (A) In non-FRDA cells there is low
level of FAST-1 (dotted arrow), normal occupancy of CTCF and no
heterochromatin formation in the 59UTR. (B) Our data are compatible
with the following model in FRDA cells: CTCF is depleted from the
59UTR, followed by increased levels (or spreading) of FAST-1 into the
59UTR (arrow), which induces H3K9me3 and HP-1 mediated hetero-
chromatin formation (filled pattern), leading to transcriptional silencing
of the FXN gene.
doi:10.1371/journal.pone.0007914.g005
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out presently, is that FAST-1 overexpression may itself displace
CTCF from the 59UTR, either directly or secondary to +1
nucleosomal modification and/or displacement. Indeed, lipopoly-
saccharide-induced overexpression of the chicken lysozyme gene is
mediated by increased antisense transcription that results in
repositioning of a nucleosome over the CTCF binding site leading
to its eviction [40]. The coincidence of the CTCF binding site in
the FXN 59UTR and the +1 nucleosome tends to support this type
of mechanism, although our data did demonstrate that FAST-1
overexpression occurred as a result of CTCF deficiency.
The discovery that HDAC inhibitors result in reversal of the
FXN transcriptional silencing has led to their use in currently
ongoing clinical trials. Our findings provide a mechanistic basis for
the transcriptional silencing of the FXN gene in Friedreich ataxia
that is consistent with this response to HDAC inhibitors, and
elucidate a rational basis for their action. Moreover, the
identification of localized CTCF depletion and increased FAST-
1 levels offer potential therapeutic targets for the specific
reactivation of the transcriptionally silenced FXN gene in FRDA.
Materials and Methods
Cell Lines
Fibroblasts from two healthy subjects (GM04503, GM07492)
and two FRDA patients (GM03665, GM04078) were obtained
from Coriell Cell Repository. Expanded GAA alleles for the two
FRDA patients were 445 & 740 triplets (GM03665), and 345 &
470 triplets (GM04078). All experiments were performed with
early passages of the four cell lines.
Electrophoretic Mobility Shift Assay
A 231-bp PCR fragment (position 2222 to +9 relative to the
initiation codon) containing the putative CTCF binding site in the
59UTR of the FXN gene was used as the probe. The end-labeled
probe was incubated with HeLa nuclear extract (5 mg; Millipore)
for 40 minutes at room temperature in binding buffer (10 mM
Tris, pH 7.5, 50 mM NaCl, 1 mM dithiothreitol, 1 mM EDTA,
5% glycerol, and poly dI-dC), and resolved on a 5% native
polyacrylamide gel. Cold competition was performed using excess
unlabeled probe, a CTCF consensus oligonucleotide (sc-2613;
Santa Cruz), or a mutant CTCF oligonucleotide (sc-2614; Santa
Cruz). Methylated probe for EMSA was generated via in vitro
methylation using M.SssI CpG methyltransferase and S-adenosyl-
methionine (New England BioLabs).
Bisulfite Sequencing for Detection of CpG Methylation
200 ng of genomic DNA was treated using the EZ DNA
Methylation-Direct Kit (Zymo Research) to convert unmethylated
cytosines to uracil. PCR was performed using the following primer
pairs: CTCF-meth-F1 59-GCTCCGTCTAGATTGTGTATG-
TATTTATTTTTTAG-39 and CTCF-meth-R1 59-GATGCG-
CTGCAGAAAATAAAACCAACTCTACC-39 followed by nested
PCR with primers: CTCF-meth-F2 59-GCTCCGTCTAGAGG-
TTGTATTTCGTGTTTTGT-39 and CTCF-meth-R2 59-GATG-
CGCTGCAGCTAAACCTAAACTAAACTAAATAAC-39.T h e
XbaI and PstI sites in the forward and reverse primers, respectively,
were used to clone the PCR products into pUC19. Twelve clones were
sequenced for each DNA sample. Cytosine to uracil conversion was
complete at all non CpG sites.
Chromatin Immunoprecipitation (ChIP)
We used the ChIP-IT Express kit (Active Motif). Immunopre-
cipitations were performed overnight at 4uC using anti-CTCF
(Millipore 07-729), anti-H3K9me3 (Millipore 17-625), anti-
H3K27me3 (Millipore 07-449), anti-HP1a (Millipore 07-346), or
anti-HP1c (Millipore 07-332). The immunoprecipitated DNA and
the input DNA were analyzed by real-time PCR using the DDCt
method on the Eppendorf RealPlex-4 Mastercycler with Power
SYBR Green PCR Mastermix (Applied Biosystems) and the
following primers:
FXN-ChIP-forward 59-TCCTGAGGTCTAACCTCTAGCTG-
C-39 and
FXN-ChIP-reverse 59-CGAGAGTCCACATGCTGCTCC-39
GAPDH-ChIP-forward 59-CCTCCCGCTTCGCTCTCT-39
and
GAPDH-ChIP-reverse 59-GGTTTCTCTCCGCCCGTCT-39
Each value of immunoprecipitated DNA, normalized to
GAPDH, was further normalized to the corresponding input
DNA. All ChIP experiments, which were performed in triplicate,
were done using two independent chromatin preparations. All
data are from the two FRDA cell lines combined versus the two
normal controls combined. The human CTCF insulator (MYC-N)
and a non-binding site (MYC-G) in the MYC gene were used as
positive and negative controls for CTCF binding [41]. The region
of GAPDH used to normalize the ChIP data was confirmed to not
enrich CTCF by comparing it with another region of the GAPDH
gene located far away from any known CTCF binding sites (using
the following primers: 59-TACTAGCGGTTTTACGGGCG-39
and 59-TCGAACAGGAGGAGCAGAGAGCGA-39). CTCF en-
richment at the APBA1 locus on chromosome 9 was tested with
primers: 59-CCTCAATCGCCTGGGAATCT-39 and 59-GCCC-
TCCCCAGCAGACA-39. Micro-ChIP was used to test the
depletion of CTCF specifically in the FXN gene. This was
essentially performed as previously described [15]. The only
modifications we implemented included the use of 25,000 cells and
optimization of the sonication step to yield a modal sheared
chromatin size of ,500 bp.
Quantitative RT-PCR
Total RNA was isolated with TriPure (Roche), and cDNA was
synthesized using the QuantiTect reverse transcription kit
(Qiagen). Relative transcript levels were measured by real-time
PCR as above, and normalized to HPRT. FXN transcript levels
were detected as previously described [6]. Detection of FAST-1
was accomplished by reverse transcription using a strand-specific
primer (FAST-RT: 59- CCAAGCAGCCTCAATTTGTG-39).
PCR was performed with FAST-F1 (59-GTGGGGGAGCAGC-
TAGAGG-39) and FAST-R1 (59-CACTTCCCAGCAAGA-
CAGC-39) (note: ‘‘F’’ and ‘‘R’’ designations are in the FAST-1
orientation). PCR for FAST-1 was performed using either Taq
DNA polymerase (Roche) or the Power SYBR Green PCR
Mastermix (Applied Biosystems), and 35 cycles of 30 s at 95uC, 30
sa t6 2 uC, and 30 s at 70uC. Relative FAST-1 levels were
quantified by real-time PCR (as above), and expression levels were
normalized to HPRT. Statistical analysis was performed with
triplicate data from two independent experiments.
siRNA Knockdown of CTCF
Stealth RNAi for CTCF (Invitrogen; 6 mg) was used to transfect
cells in 6-well plates using Lipofectamine 2000 (Invitrogen). Stealth
RNAi Negative Universal Control (Invitrogen) was used as the
scrambled sequence control. Cells were harvested 48 hr post-
transfection. CTCF knockdown was confirmed using quantitative
RT-PCR (with primers described in [41]) and western blot analysis
with anti-CTCF antibody (Millipore 07-729). b-actin (Abcam
8227) was used as the loading control for the western blot analysis.
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Figure S1 FRDA cells do not have a generalized defect of
CTCF binding. ChIP with anti-CTCF in fibroblasts from FRDA
and non-FRDA controls (CNTR) showed no reduction in
enrichment of CTCF at the MYC-N insulator and the APBA1
(Amyloid beta A4 precursor protein-binding family A member 1)
locus on chromosome 9q in vivo. Whereas the APBA1 locus showed
no difference, the MYC-N site showed a slight increase in FRDA
cells, the biological significance of which is unclear.
Found at: doi:10.1371/journal.pone.0007914.s001 (0.85 MB TIF)
Figure S2 CTCF binds in vitro to the methylated FXN 5UTR.
EMSA performed with HeLa nuclear extract and an in vitro
methylated 59UTR probe (methylation status of which was
confirmed by bisulfite sequencing) showed a similar major
complex as with the unmethylated probe. This complex was
competed away by excess cold unmethylated probe, indicating
that CTCF binds the 59UTR irrespective of methylation status
and that altered DNA methylation is unlikely to be the reason for
CTCF depletion in the FXN 59UTR in FRDA.
Found at: doi:10.1371/journal.pone.0007914.s002 (0.64 MB TIF)
Figure S3 Western blot analysis showing siRNA mediated
knockdown of CTCF protein. Fibroblasts from non-FRDA
controls, either untransfected (UT), or treated with scrambled
control siRNA (SC) or with a specific CTCF siRNA are shown.
Western blot analysis with anti-CTCF and anti b-actin antibodies
showed reduction of CTCF protein specifically in cells treated with
CTCF siRNA.
Found at: doi:10.1371/journal.pone.0007914.s003 (0.19 MB TIF)
Figure S4 Quantitative RT-PCR analysis showing siRNA
mediated knockdown of CTCF transcript. Fibroblasts from non-
FRDA controls, either untransfected (UT), or treated with
scrambled control siRNA (SC) or with a specific CTCF siRNA
are shown. Quantitative RT-PCR analysis of relative CTCF
transcript levels (normalized to HPRT) showed reduction of
CTCF transcript specifically in cells treated with CTCF siRNA.
Error bars=s.e.m.; ‘‘*’’=P,0.05.
Found at: doi:10.1371/journal.pone.0007914.s004 (0.57 MB TIF)
Figure S5 CTCF knockdown results in depletion of CTCF at
the FXN locus. Micro-ChIP assay performed on non-FRDA
fibroblasts, either untransfected (UT) or treated with scrambled
control siRNA (SC) or specific CTCF siRNA showed reduced
CTCF occupancy at the FXN locus specifically in cells treated with
CTCF siRNA. Error bars=s.e.m.; ‘‘*’’=P,0.05.
Found at: doi:10.1371/journal.pone.0007914.s005 (0.57 MB TIF)
Figure S6 CTCF knockdown results in deficiency of FXN
transcript. Quantitative RT-PCR performed on non-FRDA
fibroblasts, either untransfected (UT) or treated with scrambled
control siRNA (SC) or specific CTCF siRNA showed reduced
levels of FXN transcript (normalized to HPRT) specifically in cells
treated with CTCF siRNA. Error bars=s.e.m.; ‘‘*’’=P,0.05.
Found at: doi:10.1371/journal.pone.0007914.s006 (0.57 MB TIF)
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